Caplan Jay David 4

4 · FRACTYL HEALTH, INC. · Filed Feb 3, 2025

Form 4

Period: 2025-01-30

President, Chief Product Off.

Transactions

Exercise/Conversion
Common Stock
2025-01-31$1.70/sh+22,346$37,988→ 175,890 total
Sale
Common Stock
2025-01-31$1.81/sh−22,346$40,464→ 153,544 total
Sale
Common Stock
2025-01-30$1.95/sh−21,472$41,802→ 153,544 total
Exercise/Conversion
Stock Option
2025-01-30−21,472→ 40,270 total
Exercise: $1.70Exp: 2025-02-10→ Common Stock (21,472 underlying)
Exercise/Conversion
Stock Option
2025-01-31−22,346→ 17,924 total
Exercise: $1.70Exp: 2025-02-10→ Common Stock (22,346 underlying)
Exercise/Conversion
Common Stock
2025-01-30$1.70/sh+21,472$36,502→ 175,016 total

Holdings

Footnotes (4)

[F1]Represents sales pursuant to a Rule 10b5-1 plan that the Reporting Person entered into on September 13, 2024.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.9000 to $2.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.8000 to $1.8800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]The option is fully vested and exercisable.

Documents

1 file